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ABSTRACT
Objective To evaluate the application of non-invasive
prenatal testing (NIPT) as an alternative to invasive
diagnostic prenatal testing in pregnancies with abnormal
ultrasound findings.
Methods This was a retrospective analysis of 251
singleton and multiple pregnancies at high risk for
fetal chromosomal abnormality based on findings at
sonographic examination, in which NIPT was performed
as a first-tier genetic test. NIPT was performed
by massively parallel sequencing of cell-free DNA
in maternal plasma, allowing genome-wide detection
of whole-chromosome, as well as partial, autosomal
aneuploidy. Sex chromosomes were not analyzed,
according to the current protocol in Dutch laboratories.
Results NIPT was performed at a median gestational
age of 20 weeks, indicated by the presence of multiple
congenital anomalies (n = 13), isolated structural anoma-
lies (n = 57), increased nuchal translucency ≥ 3.5 mm
(n = 58), soft markers (n = 73), growth restriction
(n = 40) and other anomalies (n = 10). NIPT results were
normal in 224 (89.2%) pregnancies, inconclusive in one
(0.4%) and abnormal in 26 (10.4%). Most genetic aberra-
tions detected by NIPT were common whole-chromosome
aneuploidies: trisomy 21 (n = 13), trisomy 18 (n = 6)
and trisomy 13 (n = 3). Four further NIPT results were
abnormal; one was suspected of being confined placental
mosaicism and one was of maternal origin. In those with
normal NIPT results, sonographic follow-up or exami-
nation of the newborn indicated the need for diagnostic
genetic testing in 33/224 (14.7%) pregnancies. Clinically
relevant genetic aberrations were revealed in 7/224 (3.1%)
cases, two of which were whole-chromosome aneuploi-
dies: trisomy 13 and monosomy X. As sex chromosomal
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aberrations are not included in NIPT analysis, the latter
cannot be considered a false-negative result. Other dis-
cordant findings were subchromosomal aberrations (< 20
megabases, n = 2) and monogenic aberrations (n = 3).
Conclusions NIPT should not be recommended for
genetic evaluation of the etiology of ultrasound anomalies,
as both resolution and sensitivity, or negative predictive
value, are inferior to those of conventional karyotyping
and microarray analysis. Nonetheless, some pregnant
women consider NIPT to be an acceptable alternative
to invasive diagnostic testing. © 2016 The Authors.
Ultrasound in Obstetrics & Gynecology published by
John Wiley & Sons Ltd on behalf of the International
Society of Ultrasound in Obstetrics and Gynecology.
INTRODUCTION
Pregnant women at high risk for fetal chromosomal
abnormality based on findings at sonographic exam-
ination are offered prenatal genetic testing. Genetic
evaluation enables determination of the etiology of the
ultrasound anomaly, overall fetal prognosis and risk
of recurrence in future pregnancies. The information
obtained could facilitate prospective parents’ reproduc-
tive decision-making when confronted with the choice
between terminating pregnancy or continuing pregnancy
and preparing themselves for the birth of a child with a
physical and/or intellectual disability.
In cases with ultrasound anomalies, fetal genotyping is
usually performed by quantitative fluorescent polymerase
chain reaction (QF-PCR) of fetal DNA for rapid diagnosis
of (an)euploidy of chromosomes 13, 18, 21 and the sex
chromosomes. If QF-PCR results are normal, microscopic
G-band karyotyping has long been the standard approach
to detect chromosomal aberrations at a resolution
© 2016 The Authors. Ultrasound in Obstetrics & Gynecology published by John Wiley & Sons Ltd ORIGINAL PAPER
on behalf of the International Society of Ultrasound in Obstetrics and Gynecology.
722 Beulen et al.
of 5–10 megabases (Mb). At present, chromosomal
microarray analysis is recommended instead of, or as
an adjunct to, conventional karyotyping, as it allows
genome-wide analysis at a much higher resolution (up
to 1 kilobase (kb)), revealing clinically significant unbal-
anced submicroscopic aberrations1–3. However, these
techniques all require fetal tissue obtained by an invasive
diagnostic procedure, i.e. chorionic villus sampling or
amniocentesis. For a considerable number of pregnant
women at high risk for fetal chromosomal abnormality,
the associated procedure-related risk of miscarriage is a
reason to decline invasive diagnostic testing.
The development of non-invasive prenatal testing
(NIPT) by massively parallel sequencing (MPS) of cell-free
DNA in maternal plasma provides an alternative for the
detection of fetal genetic aberrations with the increased
safety of performing maternal blood sampling instead of
an invasive diagnostic procedure. NIPT detects common
whole-chromosome aneuploidy such as trisomy 21 (T21,
Down syndrome), trisomy 18 (T18, Edwards syndrome)
and trisomy 13 (T13, Patau syndrome) with high
sensitivity and specificity4. The non-invasive detection
of subchromosomal copy-number variants (CNVs), i.e.
microdeletions and microduplications, at a resolution
comparable with that of microarray analysis has been
shown to be feasible5. However, routine implementation
of the latter technique is hampered by its requirements
for significantly deeper sequencing, which is costly6.
Furthermore, extensive validation is needed to determine
accurately its detection rate and false-positive rate, which
is difficult owing to the low prevalence of specific genetic
aberrations. Nonetheless, some pregnant women at high
risk for fetal chromosomal abnormality based on findings
at sonographic examination already consider NIPT an
acceptable alternative to invasive diagnostic testing.
This study aimed to evaluate the application of NIPT
as an alternative to invasive diagnostic testing for the
detection of fetal genetic aberrations in pregnancies with
ultrasound anomalies.
METHODS
Study design and subjects
This was a retrospective study of all pregnant women
at high risk for fetal chromosomal abnormality based
on findings at sonographic examination, who underwent
NIPT as an alternative to fetal genotyping by QF-PCR and
microarray analysis at prenatal diagnostic centers linked
to the Network for Prenatal Diagnosis Nijmegen, between
April 2014 and November 2015. Ethical approval was
granted by the medical ethics committee of the Radboud
University Medical Center, Nijmegen, The Netherlands.
Counseling
Pregnant women at high risk for fetal chromosomal
abnormality based on sonographic examination were
offered prenatal genetic testing. As part of the standard
care offered in the prenatal diagnostic centers linked to the
Network for Prenatal Diagnosis Nijmegen, all prospective
parents included in the cohort received thorough pretest
counseling on the test characteristics and potential
benefits and disadvantages of different modalities for
prenatal genetic testing. Invasive diagnostic testing was
offered as the first-tier genetic test, utilizing both QF-PCR
and chromosomal microarray analysis, thereby providing
maximum information and a definitive diagnosis. Coun-
seling included information on the invasive diagnostic
procedure needed to obtain fetal tissue and the associated
procedure-related risk of miscarriage, i.e. 0.5% for
chorionic villus sampling and 0.3% for amniocentesis.
Counseling on NIPT included information on the test
being validated for the detection of only T21, T18 and
T13, thus offering limited information compared with
invasive diagnostic testing. Pregnant women and their
partners were informed that other potentially clinically
relevant abnormal test results besides T21, T18 and
T13 would be discussed with them. Furthermore, all
abnormal test results would have to be confirmed by
invasive diagnostic testing, especially when the results
would influence management of their pregnancy. Those
who decided to have NIPT as an alternative to fetal
genotyping by QF-PCR and microarray analysis provided
written informed consent for the application of NIPT as
a first-tier genetic test.
Genetic testing
For NIPT, maternal blood samples were obtained at
one of five diagnostic centers linked to the Network
for Prenatal Diagnosis Nijmegen. All samples were then
processed and analyzed at the Department of Human
Genetics of the Radboud University Medical Center in
Nijmegen, as described previously7,8. Briefly, samples
underwent centrifugation for plasma separation, followed
by manual extraction and MPS of cell-free DNA from
maternal plasma. MPS entailed either single-end 50-bp
sequencing on a SOLiD 5500 XL Genetic Analyzer
(Life Technologies, Foster City, CA, USA) or single-end
75-bp sequencing on a NextSeq 500 desktop sequencer
(Illumina, San Diego, CA, USA). After sequencing, reads
were mapped to the hg19 reference genome. Samples
were tested for fetal chromosomal aberrations using
WISECONDOR, a within-sample comparison algorithm
using GC-corrected 1-Mb genomic bins9,10. With this
algorithm, both whole-chromosome, as well as partial,
aneuploidy can be detected. A whole-chromosome fetal
trisomy or monosomy is considered detected when at least
50% of the bins of a chromosome are aberrant. Using
low sequence coverage (0.1–0.5×), aberrations smaller
than 20 Mb cannot be detected reliably owing to natural
fluctuations of read-depth frequencies along the genome.
Smaller aberrations are, therefore, considered only if
visual inspection of the plots strongly suggests a fetal
genetic aberration. Currently, in Dutch laboratories, fetal
gender and sex chromosomal aberrations are not analyzed
when performing NIPT. Furthermore, fetal fraction is
© 2016 The Authors. Ultrasound in Obstetrics & Gynecology published by John Wiley & Sons Ltd Ultrasound Obstet Gynecol 2017; 49: 721–728.
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not determined. Instead, it is assumed that the blood
sample contains sufficient cell-free fetal DNA to allow the
identification of fetal chromosomal aberrations.
If prenatal or postnatal diagnostic testing was per-
formed, QF-PCR analysis was carried out according
to standard procedures. In cases of normal QF-PCR
results, genome-wide high-resolution microarray ana-
lysis was carried out according to the manufacturer’s
specifications on an Affymetrix CytoScan HD array plat-
form (Affymetrix, Inc., Santa Clara, CA, USA). Cut-offs
for detection criteria for CNVs were set at 20 kb for
gains, 10 kb for losses and 1250 kb for regions of
homozygosity11. Where applicable, parental DNA was
analyzed to facilitate the interpretation of abnormal
microarray results. If CNVs were inherited from a healthy
parent, i.e. parents without physical or neurodevelop-
mental anomalies, they were classified as most probably
benign. Targeted DNA testing for monogenic diseases was
performed in adjunct to microarray analysis if indicated.
Data collection
Medical records were reviewed to extract the following
data: maternal age, maternal weight, gravidity, parity,
sonographic findings that indicated the need for prenatal
genetic testing, gestational age at time of blood
sampling for NIPT, results of NIPT, (additional)
findings of any follow-up sonographic examination,
results of any diagnostic genetic testing and pregnancy
outcome, including findings at the newborn examination.
Pathogenic aberrations detected by genetic testing were
classified as causative findings, unexpected diagnoses
or susceptibility loci for neurodevelopmental disorders
based on their relationship with findings of the
sonographic and/or newborn examination. Aberrations
found unintentionally in prospective parents were
classified as incidental findings12.
RESULTS
Between April 2014 and November 2015, prenatal genetic
testing was performed in 590 pregnant women at high risk
for fetal chromosomal abnormality based on sonographic
examination. NIPT was applied as the first-tier test for
the detection of genetic aberrations in 251 (42.5%)
pregnancies. Of these, 230 (91.6%) were singleton and
21 (8.4%) were multiple pregnancies. In all multiple
pregnancies, ultrasound anomalies were present in only
one of the fetuses when genetic testing was first indicated,
thus also when NIPT was performed. Characteristics of
the pregnant women included in the cohort are shown in
Table 1.
An overview of the findings from NIPT and diagnostic
genetic testing in pregnancies with sonographic anomalies
is shown in Figure 1, Tables 2–4, Table S1 and (showing
multiple gestations only) Table S2. NIPT results were
normal in 224 (89.2%) pregnancies, inconclusive in one
(0.4%) and abnormal in 26 (10.4%).
Table 1 Characteristics of 251 pregnant women with abnormal
findings at sonographic examination who had non-invasive
prenatal testing (NIPT) as first-tier genetic test
Characteristic Value
Age (years) 31 (17–44)
Maternal weight at NIPT (kg) 69 (44–123)
Singleton pregnancy 230 (91.6)
Multiple pregnancy 21 (8.4)
Primigravid 94 (37.5)
Multigravid 157 (62.5)
Nulliparous 119 (47.4)
Parous 132 (52.6)
GA at NIPT (weeks)* 20 (10–34)
Data are given as median (range) or n (%). *Gestational age (GA)
had bimodal distribution, with peaks at 12–13 weeks and at
20–21 weeks.
Abnormal NIPT result
The majority of genetic aberrations detected by NIPT
were whole-chromosome aneuploidies: 13 cases of T21,
six cases of T18, three cases of T13 and one case of trisomy
16. Follow-up diagnostic genetic testing was performed
in 21 of these 23 pregnancies.
In two cases, the findings of NIPT and diagnostic
genetic testing were discordant. In one specific case,
prenatal testing was indicated for genetic evaluation of
the etiology of multiple structural anomalies present in
one fetus of a diamniotic twin pregnancy. No structural
anomaly was observed in the other fetus when NIPT
was performed at 12 + 5 weeks’ gestation. NIPT was
abnormal, indicating the presence of T21. Follow-up
sonographic examination at 17 weeks’ gestation revealed
an atrioventricular septal defect and absent nasal bone,
suggestive of T21, in the fetus without previously detected
anomalies. QF-PCR analysis of fetal tissue obtained by
amniocentesis confirmed the presence of T21 (detected
by NIPT) in this fetus, but also detected T13 (not
detected by NIPT) in the other fetus. When NIPT was
repeated for research purposes at 17 + 5 weeks’ gestation,
both aneuploidies were detected. The pregnancy was
terminated.
In the second case with discordant results, NIPT
revealed fetal trisomy 16, or mosaic thereof, which could
be confirmed neither by karyotyping of amniotic fluid
nor by fluorescent in-situ hybridization analysis using a
probe specific for chromosome 16 (D16Z3). However,
postnatal microarray analysis revealed the presence of
maternal uniparental disomy of chromosome 16, most
probably owing to so-called ‘trisomy 16 rescue’. This,
in combination with the observed intrauterine growth
restriction and preterm birth, led to a suspected diagnosis
of confined placental mosaicism. Unfortunately, placental
material was not available for testing (Table 2).
In two cases, abnormal NIPT results were not
confirmed by diagnostic genetic testing. In one case, a
diamniotic twin pregnancy, prenatal testing was indicated
because of a high risk for fetal aneuploidy based
on prenatal screening by first-trimester combined test
© 2016 The Authors. Ultrasound in Obstetrics & Gynecology published by John Wiley & Sons Ltd Ultrasound Obstet Gynecol 2017; 49: 721–728.
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NIPT
(n = 251)
NIPT inconclusive
(n = 1; Case 1)
NIPT abnormal
(n = 26)
NIPT normal
(n = 224)
Aberrations detected by diagnostic
genetic testing (n = 12):
 Chromosomal aberrations (n = 9):
 1 T13 (Case 7)
 1 45,X (Case 8)
 1 del 14q32.2q32.33 ~3.9 Mb (Case 9)
 1 del 4p16.3p15.33 ~14.8 Mb (Wolf–
 Hirschhorn syndrome) and
 dup 10q26.11q26.3 ~15.3 Mb (Case 10)
 5 parentally inherited CNVs < 1 Mb
 Monogenic aberrations (n = 3):
 1 homozygous mutation in RNU4ATAC
 gene (MOPD1) (Case 11)
 1 hypomethylation in KCNQ1OT1 gene
 (LIT1) (Beckwith–Wiedemann
 syndrome) and gain 16p11.2
 ~610 kb (susceptibility locus) (Case 12)
 1 homozygous mutation in CFTR gene
 (delta F508) (cystic fibrosis) (Case 13)
No aberrations detected (n = 212):
 No diagnostic genetic testing
  indicated (n = 191)
 Diagnostic genetic testing normal
  (n = 21)
No consent for diagnostic
genetic testing:
 1 T18
 1 T21
 1 gain of 18p (Case 6)
Follow-up diagnostic genetic testing:
 3 T13
 5 T18
 11 T21
 1 T21 and T13 (NIPT indicated T21)
 (Case 2)
 1 UPD(16)mat (NIPT indicated T16)
 (Case 3)
 1 dup 8p23.1p11.21 ~29 Mb and
 del 8p23.3p23.1 ~6.8 Mb (Case 4)
 1 maternal dup 21q22.11 ~370 kb
 (Case 5)
Figure 1 Flowchart of results of non-invasive prenatal testing (NIPT) in 251 pregnancies with ultrasound anomaly. NIPT was by massively
parallel sequencing of cell-free DNA in maternal plasma. Diagnostic genetic testing was by quantitative fluorescent polymerase chain
reaction, karyotyping, microarray analysis or targeted DNA testing of fetal or maternal tissue. Case 1: genetic testing indicated by
polyhydramnios, NIPT did not meet quality criteria, however, visual inspection of plots repeatedly showed suspect chromosome 22 profile.
Mother had mild intellectual disability, shortened palate, mild hearing impairment, common variable immunodeficiency. Maternal array was
22q11.21(18,970,562-21,465,660)×1, ∼2.5 megabases (Mb). No further genetic testing. Resulted in live birth with no congenital anomaly.
Postnatal microarray of newborn revealed 22q11.21(18,648,867-21,798,908)×1 mat, ∼2.8 Mb. Case 2: multiple pregnancy, genetic testing
indicated by multiple structural anomalies (intrauterine growth restriction, holoprosencephaly, omphalocele, megacystis with bilateral hydro-
nephrosis) in one fetus. No structural anomaly was observed in other fetus. NIPT showed T21. Follow-up ultrasound at 17 weeks’ gestation
revealed atrioventricular septal defect and absent nasal bone in fetus without previously detected anomalies. Amniocentesis and genetic
testing showed 47,XY + 21 and 47,XY + 13. Pregnancy was terminated. Cases 3–13 summarized in Tables 2 and 3. CNV, copy number
variant; del, deletion; dup, duplication; kb, kilobases; MOPD1, microcephaly osteodysplastic primordial dwarfism Type I; T13, trisomy 13
(Patau syndrome); T16, trisomy 16; T18, trisomy 18 (Edwards syndrome); T21, trisomy 21 (Down syndrome); UPD(16)mat, maternal
uniparental disomy of chromosome 16.
(risk: T21, 1:6; T18, 1:22; T13, 1:45), with a nuchal
translucency thickness of 3.8 mm in one fetus. The risk
for fetal aneuploidy in the other fetus was not elevated.
NIPT was performed at 12 + 6 weeks’ gestation and
indicated the presence of T21. Sonographic follow-up
diagnosed intrauterine demise of the affected twin at 14
weeks. Amniocentesis was performed only on the fetus
with normal nuchal translucency. QF-PCR results were
normal.
In the second case with an abnormal NIPT result not
confirmed by diagnostic genetic testing, prenatal testing
was indicated by the presence of multiple structural
anomalies (semilobar holoprosencephaly, atrioventricular
septal defect with hypoplastic left heart) and severe
intrauterine growth restriction. Although fetal T18,
detected by NIPT, fitted the phenotype, consent for
prenatal or postnatal diagnostic testing was not given.
The pregnancy ended in intrauterine fetal demise.
Subchromosomal aberrations were detected by NIPT
in three other pregnancies (Table 2). Owing to the
relatively high region-specific Z-score in one case, a
maternal origin was suspected, which was subsequently
confirmed via microarray analysis of the mother’s
genomic DNA. Consultation with a clinical geneticist
revealed no maternal dysmorphic features, or physical
or neurodevelopmental anomaly, therefore the CNV
was classified as most probably benign. In another
case, NIPT detected accurately an inverted duplication
deletion of chromosome 8p. In the third case, a gain
of chromosome 18p was detected, however, consent for
prenatal or postnatal diagnostic confirmation was not
given. Newborn examination revealed mild dysmorphic
features and two small ventricular septal defects that
resolved spontaneously.
Normal NIPT result
Among the 224 pregnancies with normal NIPT results,
(additional) findings at sonographic follow-up or newborn
examination indicated the need for diagnostic genetic
© 2016 The Authors. Ultrasound in Obstetrics & Gynecology published by John Wiley & Sons Ltd Ultrasound Obstet Gynecol 2017; 49: 721–728.
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Table 2 Overview of cases with abnormal non-invasive prenatal test (NIPT) result other than trisomy 21, 18 or 13, in 251 pregnancies with
ultrasound anomaly
NIPT Diagnostic genetic testing
Case
Indication
for genetic
testing Timing Result Timing Test Result Outcome
Classification
of aberration
3 IUGR 15 weeks T16 16 weeks QF-PCR,
karyotype,
FISH
46,XX
46,XX
D16Z3 × 2
Preterm LB with no
congenital
anomaly, extreme
dysmaturity,
perinatal death
Causative
Postnatal Microarray arr 16p13.3p13.
2(89,561-8,914,906) × 2
hmz = UPD (16)mat*
4 NT 4.7 mm 13 weeks Gain of
8p†
16 weeks Karyotype,
microarray
46,XX,del(8)(p23.
3p23.1), dup(8)
(p23.1p11.21)
arr 8p23.3p23.1(158,
049-6,976,182) × 1 dn,
6.8 Mb, 8p23.1p11.21
(11,936,001-40,
905,009) × 3 dn,
29 Mb
TOP Causative
5 IUGR 21 weeks Gain of
21q‡
22 weeks Maternal
microarray
arr 21q22.11(33,
522,970-33,889,
304) × 3, ∼370 kb
(6 genes)
LB with no
congenital
anomaly
Incidental
6 IUGR 21 weeks Gain of
18p§
NP LB, two small VSDs
(resolved
spontaneously),
mild
dysmorphisms
*Maternal uniparental disomy of chromosome 16, most likely due to ‘trisomy 16 rescue’; placental material not available for testing.
†Software analysis showed 30-Mb gain of 8p; visual inspection of plots showed also a (smaller) 8p terminal loss. ‡Software analysis showed
10-Mb gain of 21q; visual inspection of plots showed relatively high region-specific Z-score, therefore, maternal origin was suspected;
consultation with clinical geneticist revealed no maternal dysmorphic features or physical or neurodevelopmental anomaly; copy number
variant therefore classified as most probably benign. §Software analysis showed 15-Mb gain of 18p. FISH, fluorescent in-situ hybridization;
IUGR, intrauterine growth restriction; kb, kilobases; LB, live birth; Mb, megabases; NP, not performed; NT, nuchal translucency thickness;
QF-PCR, quantitative fluorescent polymerase chain reaction; T16, trisomy 16; TOP, termination of pregnancy; VSD, ventricular septal
defect.
testing in 33 (14.7%) cases. Diagnostic testing revealed
genetic aberrations in 12 of these pregnancies, seven
(3.1%) of which were clinically relevant (Table 3). In all
other cases, newborn examination was normal or showed
congenital anomalies that did not indicate the need for
additional genetic testing.
Aside from the previously described case of a
diamniotic twin pregnancy with an abnormal NIPT result
indicating T21 but missing T13, NIPT did not detect
two other common whole-chromosome aneuploidies:
one case of T13 and one of monosomy X. As sex
chromosomal aberrations were not included in the NIPT
analysis, the latter aneuploidy cannot be considered
a false-negative result. In two other cases, clinically
relevant subchromosomal aberrations were not detected
by NIPT: ∼14.8-Mb 4p16.3p15.33 deletion, associated
with Wolf–Hirschhorn syndrome, in combination with
∼15.3-Mb 10q26.11q26.3 duplication in one case,
and a submicroscopic ∼3.9-Mb 14q32.2q32.33 deletion
in another case. Other subchromosomal aberrations
detected by postnatal diagnostic testing were parentally
inherited CNVs of< 1 Mb. As all were inherited from
a healthy parent, these were classified as most probably
benign and not clinically relevant. Targeted DNA testing
confirmed the presence of monogenic aberrations in three
other cases. These monogenic aberrations cannot be
detected by techniques based on whole-genome analysis
of CNVs, such as NIPT or microarray analysis.
If invasive diagnostic testing with QF-PCR and
chromosomal microarray analysis had been performed
as the first-tier genetic test in all pregnancies included in
the cohort, genetic aberrations would have been detected
in 12.7% instead of 10.4% of all pregnancies, excluding
parentally inherited CNVs< 1 Mb as these were most
probably benign and not clinically relevant (Table 4).
DISCUSSION
Our study evaluates the application of NIPT for
prenatal genetic testing in pregnancies at high risk for
fetal chromosomal abnormality based on findings at
sonographic examination. Our findings show that NIPT
should not be recommended as an alternative to invasive
diagnostic testing for genetic evaluation of the etiology of
ultrasound anomalies. Both resolution and sensitivity,
or negative predictive value, are inferior to those of
the diagnostic genetic test modalities currently available,
© 2016 The Authors. Ultrasound in Obstetrics & Gynecology published by John Wiley & Sons Ltd Ultrasound Obstet Gynecol 2017; 49: 721–728.
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Table 3 Overview of cases with clinically relevant aberration revealed by diagnostic genetic testing after normal non-invasive prenatal test
(NIPT) result in 251 pregnancies with ultrasound (US) anomaly
Diagnostic genetic testing
Case
Indication
for genetic
testing Timing Timing Test Result Outcome
Classification
of aberration
7 MCA 14 weeks 17 weeks QF-PCR 47,XY + 13 IUFD (US at 17
weeks)
Causative
8 Hydrops fetalis 12 weeks Postnatal QF-PCR 45,X IUFD (US at 18
weeks)
Causative
9 NT 3.9 mm 21 weeks 32 weeks Microarray 14q32.2q32.33(101,
220,548-105,080,
719) × 1 dn, 3.9 Mb
Unilateral
hydrothorax (US
at 32 weeks),
anal atresia, some
mild
dysmorphisms
Causative
10 IUGR 23 weeks Postnatal Microarray 4p16.3p15.33(68,
346-14,875,532) × 1 dn,
14.8 Mb
(Wolf–Hirschhorn
syndrome)
10q26.11q26.3(120,
145,796-135,427,
144) × 3 dn,
15.3 Mb
Severe dysmaturity,
microcephaly,
some
dysmorphisms
Causative
11 MCA 30 weeks Postnatal DNA Homozygous
pathogenic mutation
in RNU4ATAC gene
(LIT1) (MOPD1)
Severe dysmaturity,
microcephaly,
severe
intracerebral
abnormalities,
VSD, several
dysmorphisms,
bilateral rocker
bottom feet
Causative
12 Omphalocele 14 weeks Postnatal Microarray 16p11.2(29,567,296-
30,178,000) × 3 dn,
610 kb
(susceptibility locus)
DNA hypomethylation
in KCNQ1OT1 gene
(Beckwith–Wiedemann
syndrome)
Omphalocele,
unilateral duplex
collecting system
and ureterocele
(US at 18 weeks),
earlobe creases
Susceptibility
locus; causative
13 Echogenic bowel 21 weeks 23 weeks* DNA Homozygous
pathogenic mutation
in CFTR gene
(deltaF508) (cystic
fibrosis)
TOP Causative
*Parental carrier screening confirmed presence of maternal and paternal pathogenic mutations in CFTR gene (deltaF508). IUFD, intrauterine
fetal demise; IUGR, intrauterine growth restriction; kb, kilobases; Mb, megabases; MCA, multiple congenital anomalies; MOPD1, micro-
cephaly osteodysplastic primordial dwarfism Type I; NT, nuchal translucency thickness; QF-PCR, quantitative fluorescent polymerase chain
reaction; TOP, termination of pregnancy; VSD, ventricular septal defect.
i.e. conventional G-band karyotyping and chromosomal
microarray analysis.
NIPT for the detection of fetal genetic aberrations in
pregnancies with ultrasound anomalies yielded 10.4%
abnormal results. This is considerably higher than
the yield found in pregnancies at high risk for fetal
chromosomal abnormality based on a personal or family
history of chromosomal abnormality or prenatal screening
by first-trimester combined testing (5.2% abnormal
NIPT results in the same timeframe, applying the same
laboratory protocol; own unpublished data). This is in
accordance with the high prevalence of fetal genetic
aberrations in the population studied. Chromosomal and
subchromosomal genetic aberrations that can be detected
by conventional karyotyping are present in 9–19% of
fetuses with single and multiple anomalies, respectively13.
Clinically relevant submicroscopic CNVs detected by
microarray analysis are found in 5–10% of fetuses with
ultrasound anomalies and a normal karyotype1–3.
With the present state of technology, NIPT should be
able to detect common whole-chromosome aneuploidies
with high sensitivity and specificity4. However, in
this study population, two out of five cases of T13
were not detected by NIPT. Discordant findings could
possibly be explained by a low fraction of fetal DNA
within these samples, directly affecting the diagnostic
© 2016 The Authors. Ultrasound in Obstetrics & Gynecology published by John Wiley & Sons Ltd Ultrasound Obstet Gynecol 2017; 49: 721–728.
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Table 4 Diagnostic yield of non-invasive prenatal testing (NIPT)
and invasive diagnostic genetic testing by quantitative fluorescent
polymerase chain reaction (QF-PCR) and chromosomal microarray
analysis in 251 pregnancies with ultrasound anomaly
Diagnostic yield
Indication
for genetic testing NIPT
QF-PCR and
microarray analysis*
Multiple structural
anomalies
7/13 (53.8) 8/13 (61.5)
Structural anomaly 4/57 (7.0) 5/57 (8.8)†
NT ≥ 3.5 mm 9/58 (15.5) 10/58 (17.2)
Sonographic marker 2/73 (2.7) 2/73 (2.7)
IUGR 4/40 (10.0) 5/40 (12.5)
Other 0/10 (0.0) 2/10 (20.0)‡
Total 26/251 (10.4) 32/251 (12.7)
Data are given as n/N (%). *Yield of prenatal genetic testing if
invasive diagnostic testing was performed in all pregnancies in
cohort. Parentally inherited copy number variants< 1 megabase
(Mb) classified as most probably benign and not clinically relevant
and monogenic aberrations that would only have been detected by
targeted DNA testing were not taken into consideration. †Including
Case 12: normal NIPT result, in which 16p11.2 ∼ 610 kilobase
gain (susceptibility locus) would have been detected by
chromosomal microarray analysis, but (clinically relevant)
hypomethylation of KCNQ1OT1 gene resulting in
Beckwith–Wiedemann syndrome would not. ‡Including Case 1:
inconclusive NIPT result in which 22q11.21 ∼ 2.8 Mb deletion
would have been detected by chromosomal microarray analysis
despite maternal carrier status. IUGR, intrauterine growth
restriction; NT, nuchal translucency thickness.
reliability of NIPT. Research has shown that the fetal
fraction is decreased when T13 is present in the
fetus14,15. Furthermore, in multiple pregnancies the fetal
fraction per fetus is reduced, leading to an increased
risk of false-negative results16. Unfortunately, in Dutch
laboratories, the fraction of fetal DNA is not at
present determined when performing NIPT, therefore
no additional information regarding fetal fraction was
available.
In the presence of sufficient fetal DNA, the resolution
and sensitivity of NIPT are limited mainly by sequencing
depth6,17. It is to be expected that, in due time,
technological development will enable non-invasive
detection of small pathogenic genetic aberrations, such
as microdeletions and microduplications. However, even
if the resolution and sensitivity of NIPT were comparable
with those of microarray analysis, NIPT cannot be
considered a diagnostic test. The present study shows
that discordant findings between NIPT and true fetal
genotype are unavoidable owing to biological phenomena
such as confined placental mosaicism and maternal genetic
aberrations.
Although microarray analysis is recommended as the
first-tier test for the detection of fetal genetic aberrations
in pregnancies with ultrasound anomalies, for some
pregnant women and their partners, NIPT represents
an acceptable alternative to invasive diagnostic testing.
Prospective parents might evaluate differently the benefits
and disadvantages of different test modalities depending
on many factors, i.e. the value of the information provided
by the test, the intention to terminate or continue
pregnancy in case of (relevant) fetal genetic aberrations,
and acceptability of the risk of a procedure-related
miscarriage18. Therefore, the choice of a prenatal test
should be theirs to make, provided they receive thorough
pretest counseling on the characteristics of genetic tests
currently available. Pregnant women and their partners
should be made fully aware that the information provided
by NIPT is inferior to the information provided by
invasive diagnostic testing. Furthermore, pregnant women
should realize that there is a chance of unlooked-for
findings in the form of maternal CNVs.
For pregnancies included in this study, fear of
a procedure-related miscarriage and unwillingness to
terminate the pregnancy in case of fetal chromosomal
abnormality were often noted as reasons for declining
invasive diagnostic testing. Unfortunately, the data
extracted from medical records were insufficient for
further analysis of prospective parents’ decision-making.
Prospective studies comparing the utility of invasive
diagnostic testing with the utility of NIPT for genetic
evaluation of pregnancies with ultrasound anomalies
should be performed to enable further analysis of
prospective parents’ decision-making regarding prenatal
genetic testing, e.g. preferences, reasons for choosing
a certain test modality, informed decision-making,
decisional conflict and decision regret.
This study is limited by the fact that, although complete
follow-up of pregnancy outcomes was ascertained,
diagnostic genetic testing was not performed when
sonography or newborn examination did not call for it.
In conclusion, NIPT should not be recommended for
genetic evaluation of the etiology of ultrasound anomalies,
as both resolution and sensitivity, or negative predictive
value, are inferior to those of conventional karyotyping
and microarray analysis. Nonetheless, some pregnant
women consider NIPT to be an acceptable alternative
to invasive diagnostic testing.
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SUPPORTING INFORMATION ON THE INTERNET
The following supporting information may be found in the online version of this article:
Table S1 Ultrasound anomaly indicating genetic testing, genetic test results and pregnancy outcome in 251
women who had non-invasive prenatal testing (NIPT)
Table S2 Overview of genetic findings by non-invasive prenatal testing (NIPT) and diagnostic genetic testing
in 21 multiple pregnancies with ultrasound (US) anomaly
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